SCHEMBL5138086

SCHEMBL5138086

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccccc1OCC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
TSHR P16473 4/20 0.40
MAPT P10636 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
POLB P06746 2/20 0.37
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
PDE4B Q07343 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
RECQL P46063 1/20 0.35
CYP3A4 P08684 2/20 0.35
NR1H3 Q13133 1/20 0.34
BCHE P06276 2/20 0.34
ACHE P22303 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137485 0.96 C5AR1 (0.42) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5135183 0.93 PDE4B (0.39) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5137575 0.93 C5AR1 (0.42) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5074328 0.92 DRD2 (0.38) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5138021 0.91 C5AR1 (0.43) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5135193 0.91 BCHE (0.43) C5AR1TSHRMAPTBCHEACHE
SCHEMBL5069962 0.87 BCHE (0.45) C5AR1TSHRBCHEACHE
SCHEMBL5134561 0.87 C5AR1 (0.45) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5137651 0.86 C5AR1 (0.42) C5AR1TSHRMAPTKDM4EALDH1A1
SCHEMBL5072435 0.86 C5AR1 (0.46) C5AR1TSHRMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed